Evidence map›Paper›PMID 42099990›Full record

ArticleMaterials today. Bio2026

Nano-bionic bacteria armed adoptive macrophage therapy against bladder cancer.

Peng Wang, Fangdie Ye, Hairui Wang, Jing Liu, Bo Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Peng WangDepartment of Urology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Fangdie YeFudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, 200000, China.
Hairui WangDepartment of Radiology, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Jing LiuDepartment of Obstetrics, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Bo LiDepartment of Urology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bladder cancer is a highly malignant tumor with limited treatment options. Although adoptive cell therapy has shown promise in oncology, its efficacy is often constrained by poor intrinsic antitumor activity and a highly immunosuppressive tumor microenvironment. To address these challenges, this study develops a novel living adoptive macrophage therapy armed with nano-bionic bacteria for bladder cancer treatment. Specifically, hollow manganese dioxide (MnO

Indexed as

Adoptive macrophage therapyBladder cancerNano-bionic bacteriaSTING pathwayTumor microenvironment

Identifiers

PMID42099990
PMCPMC13148008

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.